Inhibition of interleukin-6 signaling attenuates aortitis, left ventricular hypertrophy and arthritis in interleukin-1 receptor antagonist deficient mice. Issue 20 (30th October 2020)
- Record Type:
- Journal Article
- Title:
- Inhibition of interleukin-6 signaling attenuates aortitis, left ventricular hypertrophy and arthritis in interleukin-1 receptor antagonist deficient mice. Issue 20 (30th October 2020)
- Main Title:
- Inhibition of interleukin-6 signaling attenuates aortitis, left ventricular hypertrophy and arthritis in interleukin-1 receptor antagonist deficient mice
- Authors:
- Hada, Yoshiko
Uchida, Haruhito A.
Mukai, Tomoyuki
Kojima, Fumiaki
Yoshida, Masashi
Takeuchi, Hidemi
Kakio, Yuki
Otaka, Nozomu
Morita, Yoshitaka
Wada, Jun - Abstract:
- Abstract: The aim of the present study was to examine whether inhibition of Interleukin (IL)-6 signaling by MR16-1, an IL-6 receptor antibody, attenuates aortitis, cardiac hypertrophy, and arthritis in IL-1 receptor antagonist deficient (IL-1RA KO) mice. Four weeks old mice were intraperitoneally administered with either MR16-1 or non-immune IgG at dosages that were adjusted over time for 5 weeks. These mice were stratified into four groups: MR16-1 treatment groups, KO/MR low group (first 2.0 mg, following 0.5 mg/week, n =14) and KO/MR high group (first 4.0 mg, following 2.0 mg/week, n =19) in IL-1RA KO mice, and IgG treatment groups, KO/IgG group (first 2.0 mg, following 1.0 mg/week, n =22) in IL-1RA KO mice, and wild/IgG group (first 2.0 mg, following 1.0 mg/week, n =17) in wild mice. Aortitis, cardiac hypertrophy and arthropathy were histologically analyzed. Sixty-eight percent of the KO/IgG group developed aortitis (53% developed severe aortitis). In contrast, only 21% of the KO/MR high group developed mild aortitis, without severe aortitis ( P <0.0 1, vs KO/IgG group). Infiltration of inflammatory cells, such as neutrophils, T cells, and macrophages, was frequently observed around aortic sinus of the KO/IgG group. Left ventricle and cardiomyocyte hypertrophy were observed in IL-1RA KO mice. Administration of high dosage of MR16-1 significantly suppressed cardiomyocyte hypertrophy. MR16-1 attenuated the incidence and severity of arthritis in IL-1RA KO mice in aAbstract: The aim of the present study was to examine whether inhibition of Interleukin (IL)-6 signaling by MR16-1, an IL-6 receptor antibody, attenuates aortitis, cardiac hypertrophy, and arthritis in IL-1 receptor antagonist deficient (IL-1RA KO) mice. Four weeks old mice were intraperitoneally administered with either MR16-1 or non-immune IgG at dosages that were adjusted over time for 5 weeks. These mice were stratified into four groups: MR16-1 treatment groups, KO/MR low group (first 2.0 mg, following 0.5 mg/week, n =14) and KO/MR high group (first 4.0 mg, following 2.0 mg/week, n =19) in IL-1RA KO mice, and IgG treatment groups, KO/IgG group (first 2.0 mg, following 1.0 mg/week, n =22) in IL-1RA KO mice, and wild/IgG group (first 2.0 mg, following 1.0 mg/week, n =17) in wild mice. Aortitis, cardiac hypertrophy and arthropathy were histologically analyzed. Sixty-eight percent of the KO/IgG group developed aortitis (53% developed severe aortitis). In contrast, only 21% of the KO/MR high group developed mild aortitis, without severe aortitis ( P <0.0 1, vs KO/IgG group). Infiltration of inflammatory cells, such as neutrophils, T cells, and macrophages, was frequently observed around aortic sinus of the KO/IgG group. Left ventricle and cardiomyocyte hypertrophy were observed in IL-1RA KO mice. Administration of high dosage of MR16-1 significantly suppressed cardiomyocyte hypertrophy. MR16-1 attenuated the incidence and severity of arthritis in IL-1RA KO mice in a dose-dependent manner. In conclusion, blockade of IL-6 signaling may exert a beneficial effect to attenuate severe aortitis, left ventricle hypertrophy, and arthritis. … (more)
- Is Part Of:
- Clinical science. Volume 134:Issue 20(2020)
- Journal:
- Clinical science
- Issue:
- Volume 134:Issue 20(2020)
- Issue Display:
- Volume 134, Issue 20 (2020)
- Year:
- 2020
- Volume:
- 134
- Issue:
- 20
- Issue Sort Value:
- 2020-0134-0020-0000
- Page Start:
- 2771
- Page End:
- 2787
- Publication Date:
- 2020-10-30
- Subjects:
- MR16-1 -- interleukin-1 receptor antagonist -- aortitis -- arthritis -- LV hypertrophy
Medicine -- Periodicals
Biochemistry -- Periodicals
616 - Journal URLs:
- https://portlandpress.com/clinsci ↗
- DOI:
- 10.1042/CS20201036 ↗
- Languages:
- English
- ISSNs:
- 0143-5221
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 15433.xml